Metraipolis › archive › dc_e3cf44d81963

Neoadjuvant almonertinib as a bridging strategy to surgery in resectable lung cancer with active COVID-19: a case report — Europe PMC PMID:42131806

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42131806
DOI
10.3389/fphar.2026.1808763
License (as archived)
solo-consultazione
Archived
2026-11-03T01:51:22.779Z
SHA-256 of the archived text
006880953ef2d19842f6914fec2654680ee0f9d992090d0660b9533ec7910375
Stable URL of this page
https://metraipolis.com/documento/dc_e3cf44d81963

How to cite

Neoadjuvant almonertinib as a bridging strategy to surgery in resectable lung cancer with active COVID-19: a case report — Europe PMC PMID:42131806 — Europe PMC (en), https://europepmc.org/article/MED/42131806 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e3cf44d81963 (Metraipolis archive dc_e3cf44d81963, sha256 006880953ef2d19842f6914fec2654680ee0f9d992090d0660b9533ec7910375)
BibTeX
@misc{dce3cf44d81963,
  title = {Neoadjuvant almonertinib as a bridging strategy to surgery in resectable lung cancer with active COVID-19: a case report — Europe PMC PMID:42131806},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42131806},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e3cf44d81963; sha256 006880953ef2d19842f6914fec2654680ee0f9d992090d0660b9533ec7910375},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42131806. Agents can read the archived copy with the MCP tool read_document.